xinbang phar.(SZ:002390)2022-12-08 01:28Sales Performance - Sales of Yixinshu and Maixuekang exceeded 100 million yuan from January to September 2015, showing stable growth compared to the same period last year [3] - These two products are currently the top sales items in the company's pharmaceutical sector [3] Medical Services - Hospital operations are normal with steady income growth; bed occupancy rates exceed 100% at the Tumor Hospital and Baiyun Hospital [3] - In May 2015, 300 new beds were added at the Tumor Hospital, and 220 beds were opened at the Renhuai Xinchao Hospital in June [3] - The company is focusing on talent development and optimizing its workforce to ensure sustainable growth in medical services [3][4] Profitability - The current net profit margin for medical services is below 6%, with plans to improve profitability through better management and increased bed capacity [4] - The medical business revenue accounted for 68% of the main business income from January to September 2015 [4] Business Development - The company’s subsidiary, Tongde Pharmaceutical, completed its production line and received GMP certification at the beginning of the year [5] - The major asset restructuring with Zhongtai Biochemical is under review by the regulatory authority, with updates to be disclosed in due course [5][6] Strategic Planning - The company aims to enhance its product structure and optimize its drug distribution network through both organic growth and acquisitions [6] - The "Guiyi Cloud" project is underway, focusing on internet medical services, with initial success in establishing a customer base and service functionalities [6]